CURE

Understanding Squamous Cell Lung Cancer and Common Treatment Paths

Squamous cell carcinoma treatment varies by stage, involving surgery, radiation, and systemic therapies based on cancer ...
The Pharma Letter

Gotistobart Phase III data: a potentially best-in-class CTLA-4 mAb in squamous NSCLC and beyond

The release of Phase III Stage 1 data for gotistobart (BNT316/ONC-392) at NACLC 2025 marks one of the most significant ...

5 unexpected skin symptoms that could signal lung cancer

Sometimes, lung cancer can show itself in unexpected ways through the skin. While these skin symptoms are less common, they can serve as important early clues that the disease is affecting areas ...

US approves oral drug for adults with rare type of lung cancer after early clinical trials globally

Sevabertinib showed promise in early trials for non-squamous non-small-cell lung cancer with HER2 mutations. Read more at ...
TMCnet

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first ...
Cure Today

FDA Approves Hernexeos for Non-Squamous Non-Small Cell Lung Cancer

Hernexeos (zongertinib) received FDA accelerated approval for unresectable or metastatic non-squamous NSCLC with HER2 TKD mutations after prior treatment. The Beamion LUNG-1 trial showed a 75% ...